These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 19583031)

  • 1. [Tolerance study of a triple first-line antiretroviral combination zidovudine, lamivudine and efavirenz in Dakar, Senegal].
    Seydi M; Diop SA; Dieng AB; Tekpa G; Soumaré M; Diouf A; Niang Kh; Lakh A; Ndiaye I; Fall MB; Diop BM; Sow A; Sow PS
    Bull Soc Pathol Exot; 2009 May; 102(2):99-100. PubMed ID: 19583031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
    Laurent C; Tchatchueng Mbougua JB; Ngom Guèye NF; Etard JF; Diouf A; Landman R; Molinari N; Girard PM; Sow PS; Ndoye I; Delaporte E;
    Trop Med Int Health; 2011 Feb; 16(2):217-22. PubMed ID: 21087377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
    Crespo M; Ribera E; Suárez-Lozano I; Domingo P; Pedrol E; López-Aldeguer J; Muñoz A; Viladés C; Sánchez T; Viciana P; Teira R; García-Alcalde ML; Vergara A; Lozano F; Galindo MJ; Cosin J; Roca B; Terrón A; Geijo P; Vidal F; Garrido M;
    J Antimicrob Chemother; 2009 Jan; 63(1):189-96. PubMed ID: 18988678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative study of two anti-antiretroviral protocols used for treatment of a cohort of HIV 1-positive patients followed at the Institute of Public Health and Hygiene in Dakar, Senegal].
    Sow PG; Dia AT; Diallo PD; Traore ; Gaye AM
    Med Trop (Mars); 2011 Apr; 71(2):202-3. PubMed ID: 21695888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
    Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E;
    Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
    DeJesus E; Herrera G; Teofilo E; Gerstoft J; Buendia CB; Brand JD; Brothers CH; Hernandez J; Castillo SA; Bonny T; Lanier ER; Scott TR;
    Clin Infect Dis; 2004 Oct; 39(7):1038-46. PubMed ID: 15472858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of tolerance of zidovudine-lamivudine-nevirapine combination in HIV 1 patients in Fann Teaching Hospital in Dakar].
    Fortes Déguénonvo L; Diop SA; Leye MM; Seydi M; Dieng AB; Bentaleb H; Diouf A; Lakhe NA; Ka D; Cisse VM; Dia Badiane NM; Manga MN; Ndour CT; Soumaré M; Diop BM; Sow PS
    Bull Soc Pathol Exot; 2013 Oct; 106(4):244-7. PubMed ID: 24150730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and tolerance of tenofovir-lamivudine-efavirenz combination in HIV-1 patients in Fann Teaching Hospital in Dakar].
    Diop SA; Fortes-Déguénonvo L; Seydi M; Dieng AB; Basse CD; Manga NM; Dia NM; Ndaw G; Ndour CT; Soumaré M; Diop BM; Sow PS
    Bull Soc Pathol Exot; 2013 Feb; 106(1):22-6. PubMed ID: 23247755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
    Landovitz RJ; Angel JB; Hoffmann C; Horst H; Opravil M; Long J; Greaves W; Fätkenheuer G
    J Infect Dis; 2008 Oct; 198(8):1113-22. PubMed ID: 18783318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profound and unanticipated anemia with lamivudine-zidovudine combination therapy in zidovudine-experienced patients with HIV infection.
    Hester EK; Peacock JE
    AIDS; 1998 Mar; 12(4):439-40. PubMed ID: 9520175
    [No Abstract]   [Full Text] [Related]  

  • 12. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
    Michelet C; Bellissant E; Ruffault A; Arvieux C; Delfraissy JF; Raffi F; Bazin C; Renard I; Sébille V; Chauvin JP; Dohin E; Cartier F
    Clin Pharmacol Ther; 1999 Jun; 65(6):661-71. PubMed ID: 10391672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.
    Prescrire Int; 2004 Oct; 13(73):180-2. PubMed ID: 15499699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
    Gartland M;
    Antivir Ther; 2001 Jun; 6(2):127-34. PubMed ID: 11491417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study.
    Sierra-Madero J; Di Perri G; Wood R; Saag M; Frank I; Craig C; Burnside R; McCracken J; Pontani D; Goodrich J; Heera J; Mayer H
    HIV Clin Trials; 2010; 11(3):125-32. PubMed ID: 20736149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy.
    Tashima KT; Caliendo AM; Ahmad M; Gormley JM; Fiske WD; Brennan JM; Flanigan TP
    J Infect Dis; 1999 Sep; 180(3):862-4. PubMed ID: 10438381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
    Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
    N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection.
    Tashima K; Staszewski S; Nelson M; Rachlis A; Skiest D; Stryker R; Bessen L; Overfield S; Ruiz N; Wirtz V
    AIDS; 2008 Jan; 22(2):275-9. PubMed ID: 18097230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
    Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
    N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.